Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MIRA PHARMACEUTICALS, INC. (MIRA)

MIRA Pharmaceuticals submits Ketamir-2 Phase 2a protocol for IRB review

Neutral Impact 2 of 5 other Written later

MIRA Pharmaceuticals said the Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neuropathy has been submitted for Institutional Review Board review at a leading cancer research institution, after incorporating FDA feedback. The company is targeting site initiation in the first quarter of 2027, subject to IRB review and other routine site activation requirements. The filing contains no financial figures, so the update is a clinical development milestone rather than a change to reported results.

Key points

  • Phase 2a protocol submitted for IRB review at a leading cancer research institution, after FDA review and comments
  • Site initiation targeted for the first quarter of 2027, subject to IRB review and routine site activation requirements
  • Randomized, placebo-controlled, three-period crossover study with 300 mg and 600 mg Ketamir-2 doses and seven-day treatment periods
  • Dr. Itzchak Angel to present Ketamir-2 data at a conference in Tokyo, Japan, on October 5–6, 2026

The filing

CompanyMIRA PHARMACEUTICALS, INC. (MIRA)
Form8-K, current report
Filed with the SECSep 17, 2026, 8:30 AM ET
Accession number0001493152-26-043051

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.